Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
Date:2/17/2011

o be steady.  Our total revenues for the fourth quarter of 2010 were $101.6 million, the first time we have exceeded $100 million for the quarter."

Net Product Revenue (in millions)Three Months Ended December 31,Years Ended December 31, 20102009$ Change% Change20102009$ Change% ChangeNaglazyme (1) $

45.1$

44.4$

0.71.6%$

192.7$

168.7$

24.014.2%Kuvan (2) 27.322.74.620.3%99.476.822.629.4%Firdapse (3) 3.00.03.0N/A6.40.06.4N/A(1) Changes in foreign currency rates, net of hedges, had a negative $0.1 million impact on Naglazyme sales in the three months ended December 31, 2010 and a negative $1.7 million impact on Naglazyme sales for the year ended December 31, 2010.  Naglazyme revenues experience quarterly fluctuations due to the timing of government ordering patterns in certain countries.

(2) The quantity of commercial tablets dispensed to patients in the U.S. increased 5.0 percent in the fourth quarter of 2010 compared to the third quarter of 2010 and increased 16.4 percent in the fourth quarter of 2010 compared to the fourth quarter of 2009.

(3) A product for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS) which was launched in the EU in April 2010. Three Months Ended December 31, Years Ended December 31,20102009$ Change% Change 20102009$ Change% Change Aldurazyme revenue reported by Genzyme (4) $

42.5 $

38.7 $

 3.8 9.8%$

166.8 $

155.1 $

11.7 7.5%Royalties due from Genzyme 17.8 15.7  2.1   68.0   61.8   6.2 Incremental (previously recognized) Aldurazyme
product
transfer
revenue   5.3   1.1  4.2 3.2 8.4  (5.2)Total Aldurazyme net product revenues (5)$

23.1 $

16.8 $

 6.3 $

  71.2 $

  70.2 $

  1.0 (4) Changes in foreign currency rates caused a decrease to Aldurazym
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
2. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
3. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
4. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
5. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
6. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
7. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
8. BioMarin Announces Third Quarter 2010 Financial Results
9. BioMarin to Host a Research and Development Day on October 19th
10. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
11. BioMarin to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited (ASX:BNO, ... development of innovative therapeutics for the treatment of diseases ... announced that its BNC101 IND submission has passed review ... plans to initiate a Phase 1 clinical trial in ... metastatic pancreatic cancer prior to 31 December 2015. ...
(Date:8/30/2015)... y LONDRES, August 30, 2015 ... visión holística de l cuidado al ... trayecto   Royal Philips  ... debut europeo de IntelliSpace Cardiovascular , un sistema ... sofisticadas herramientas para acceder, analizar y compartir imágenes cardiovasculares ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3
... 25, 2011 Imagenetix, Inc. (OTC Bulletin Board: IAGX ... December 31, 2010. Net sales decreased 4% for the third quarter ... period of last year. A loss of $1,202,000, $0.10 per share, ... to a net loss of $294,000, $.03 per share, for the ...
... Accuray Incorporated (Nasdaq: ARAY ), a ... its Senior Vice President, General Counsel and Corporate Secretary, ... Company" by the Silicon Valley/San Jose Business Journal ... of their ,Best Bay Area Corporate Counsel Awards,. This annual ...
Cached Medicine Technology:Imagenetix, Inc. Reports Third Quarter 2011 Results 2Imagenetix, Inc. Reports Third Quarter 2011 Results 3Accuray's General Counsel Wins Best Bay Area Corporate Counsel Award 2Accuray's General Counsel Wins Best Bay Area Corporate Counsel Award 3Accuray's General Counsel Wins Best Bay Area Corporate Counsel Award 4
(Date:8/31/2015)... ... 31, 2015 , ... Wyoming Medical Center, an acute care ... Clinical Documentation Improvement (CDI) and medical coding needs. Based on a proprietary Natural ... is an enterprise-level coding solution that combines CDI, Coding, Quality and Compliance Auditing ...
(Date:8/31/2015)... CA (PRWEB) , ... August 31, 2015 , ... Castle ... to the practice. Dr. Pedram Ghasri is a graduate of the University of California, ... and continued his studies at the University of California, Irvine Medical School. As a ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... “My mother ... said an inventor, from Hagerhill, Ky. “I thought there could be a comfortable way ... Protector. , The Nasal Cannula Ear Protector offers a more secure way to anchor ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... A year ... the team is preparing to release a new issue commemorating the successful first year. ... information they need for a potentially difficult time in their lives,” says Melissa Wolfert, ...
(Date:8/31/2015)... Los Angeles, ACA (PRWEB) , ... August 31, 2015 , ... ... filling a growing niche in the digital healthcare industry. , Consumer driven health ... the field: one in an advisory and strategic role to the company, and another ...
Breaking Medicine News(10 mins):Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 3Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 4Health News:Castle Dermatology Institute Now Welcomes Dr. Pedram Ghasri to the Practice 2Health News:InventHelp® Inventor Designs Nasal Cannula Ear Protector (AVZ-1217) 2Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 2Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 3Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 3
... beating heart transplant for a 58-year-old man and says the ... Bruce Rosengard, at Papworth Hospital in Cambridge, led the team ... be kept warm as to body temperature and beating before ... removed organs are usually placed on ice and transferred to ...
... a Canadian National research project children’s blood here are ... PCBs to flame retardants//. ,A report by Toronto-based ... with even higher levels than their parents., ,On ... in the blood and urine samples of subjects. Some ...
... second highest success rate in heart surgeries, ensuring that 99.6 ... stories, the group's chairman Prathap C Reddy said here today. ... he said while the hospital that had the highest success ... cost effective as it charged less than 4,000 dollars. ...
... Osteoporosis (IOF WCO), the world's largest Scientific congress devoted ... June 2, in Toronto, Canada//. ,Professor Rene ... that this year's congress attracted 720 abstracts, more than ... 2004 in Rio de Janeiro, Brazil. ,On ...
... sex during the final weeks of pregnancy is not a trigger ... popular myth, that has deterred many couples enjoy physical pleasure during ... a relief., ,A study was conducted among 93 women, ... of their pregnancy. The finding revealed that women, who enjoyed the ...
... emerged victorious in a historic Supreme Court case around a ... with the ruling providing expanded access to private care//. ... from any (private) coverage. It’s a violation of the judgment. ... and eventually to die,' Chaoulli said. ,In a ...
Cached Medicine News:
... new generation of posterior stabilized knee ... the following: Patellar flange mates with ... machined condyles assure precise, repeatable kinematics ... and patella to reduce wear. Constant ...
... total knee prosthesis stems from many years ... and manufacturing technologies have been used in ... well as a favorable pressure distribution pattern ... wear to a minimum. The inherent design ...
The Balanced Knee System provides instrumentation designed to achieve proper tissue balancing and alignment with user-friendly instrumentation that provides reproducible results....
... Knee System provides anatomical replacement of all ... preserving the stabilizing Anterior and Posterior Ligaments, ... of the knee. All the components in ... and are equally proportioned and contoured to ...
Medicine Products: